Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

Diabetologia

Volumn 48, Issue 5, 2005, Pages 838-848

  Chapman, I ^b,c   Parker, B ^b,c   Doran, S ^b,c   Feinle Bisset, C ^b,c   Wishart, J ^b,c   Strobel, S ^a   Wang, Y ^a   Burns, C ^a   Lush, C ^a   Weyer, C ^a   Horowitz, M ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Amylin; Hunger; Obesity; Peptide hormones; Satiety

Indexed keywords

AMYLIN; ANOREXIGENIC AGENT; CHOLECYSTOKININ; GLUCAGON LIKE PEPTIDE 1; INSULIN; METFORMIN; PEPTIDE YY; PLACEBO; PRAMLINTIDE;

ADULT; AGED; ARTICLE; BODY MASS; CALORIC INTAKE; CHOLECYSTOKININ BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FOOD INTAKE; GASTROINTESTINAL TOXICITY; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SATIETY; SIDE EFFECT; TEST MEAL; VISUAL ANALOG SCALE;

ADULT; AMYLOID; BODY MASS INDEX; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENERGY INTAKE; ENERGY METABOLISM; FEMALE; HUMANS; HUNGER; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OBESITY; PLACEBOS; SATIATION;

EID: 18844392661     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1732-4     Document Type: Article

References (49)

1. Druce M, Bloom SR (2003) Central regulators of food intake. Curr Opin Clin Nutr Metab Care 6:361-367
2. Wynne K, Stanley S, Bloom S (2004) The gut and regulation of body weight. J Clin Endocrinol Metab 89:2576-2582
3. Druce MR, Small CJ, Bloom SR (2004) Minireview: gut peptides regulating satiety. Endocrinology 145:2660-2665
4. Stanley S, Wynne K, Bloom S (2004) Gastrointestinal satiety signals: III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide. Am J Physiol Gastrointest Liver Physiol 286:G693-G697
5. Halford JC, Cooper GD, Dovey TM (2004) The pharmacology of human appetite expression. Curr Drug Targets 5:221-240
6. Wren AM, Seal LJ, Cohen MA et al (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992
7. Pi-Sunyer X, Kissileff HR, Thornton J, Smith GP (1982) C-terminal octapeptide of cholecystokinin decreases food intake in obese men. Physiol Behav 29:627-630
8. Rayner CK, Park HS, Doran SM, Chapman IM, Horowitz M (2000) Effects of cholecystokinin on appetite and pyloric motility during physiological hyperglycemia. Am J Physiol Gastrointest Liver Physiol 278:G98-G104
9. Gutzwiller JP, Drewe J, Goke B et al (1999) Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276:R1541-R1544
10. Naslund E, Barkeling B, King N et al (1999) Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes 23:304-311
11. Flint A, Raben A, Astrup A, Holst JJ (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515-520
12. Cohen MA, Ellis SM, Le Roux CW et al (2003) Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88:4696-4701
13. Batterham RL, Cowley MA, Small CJ et al (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418:650-654
14. Batterham RL, Cohen MA, Ellis SM et al (2003) Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349:941-948
15. Geary N, Kissileff HR, Pi-Sunyer FX, Hinton V. (1992) Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. Am J Physiol 262:R975-R980
16. Batterham RL, Le Roux CW, Cohen MA et al (2003) Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 88:3989-3992
17. Lieverse RJ, Jansen JB, Masclee AM, Lamers CB (1995) Effects of somatostatin on human satiety. Neuroendocrinology 61:112-116
18. Young AA (1997) Amylin's physiology and its role in diabetes. Curr Opin Endocrinol Diabetes 4:282-290
19. Beaumont K, Kenney MA, Young AA, Rink TJ (1993) High affinity amylin binding sites in rat brain. Mol Pharmacol 44:493-497
20. Sexton PM, Paxinos G, Kenney MA, Wookey PJ, Beaumont K (1994) In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 62:553-567
21. Muff R, Buhlmann N, Fischer JA, Born W (1999) An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology 140:2924-2927
22. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, Woods SC (2000) Amylin: a novel action in the brain to reduce body weight. Endocrinology 141:850-853
23. Lutz TA, Mollet A, Rushing PA, Riediger T, Scharrer E (2001) The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int J Obes Relat Metab Disord 25:1005-1011
24. Rushing PA, Lutz TA, Seeley RJ, Woods SC (2000) Amylin and insulin interact to reduce food intake in rats. Horm Metab Res 32:62-66
25. Mack C, Hoyt J, Moore C, Jodka C, Sams-Dodd F (2003) Sustained reduction in food intake and body weight in high fatfed rats during 28-day amylin infusion. Diabetes 52[Suppl 1]: A389 (Abstract 1690-P)
26. Rushing PA, Hagan MM, Seeley RJ et al (2001) Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology 142:5035-5038
27. Reidelberger RD, Haver AC, Arnelo U, Smith DD, Schaffert CS, Permert J (2004) Amylin receptor blockade stimulates food intake in rats. Am J Physiol 287:R568-R574
28. Weyer C, Maggs DG, Young AA, Kolterman OG (2001) Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 7:1353-1373
29. Edelman SV, Weyer C (2002) Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second β-cell hormone. Diabetes Technol Ther 4:175-189
30. Maggs DG, Fineman MS, Kornstein J et al (2004) Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose timing study. Diabetes Metab Res Rev 20:55-60
31. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG (2002) The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 34:504-508
32. Vella A, Lee JS, Camilleri M et al (2002) Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil 14:123-131
33. Whitehouse FW, Kruger D, Fineman MS et al (2002) A randomized study and open label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25:724-730
34. Ratner RE, Want LL, Fineman MS et al (2002) Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated patients with type 2 diabetes. Diabetes Technol Ther 4:51-61
35. Hollander PA, Levy P, Fineman MS et al (2003) Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes mellitus: a one year randomized controlled trial. Diabetes Care 26:784-790
36. Hollander P, Fineman MS, Ruggles JA et al (2004) Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 12:661-668
37. Martini MC, Lampe JW, Slavin JL, Kurzer MS (1994) Effect of the menstrual cycle on energy and nutrient intake. Am J Clin Nutr 60:895-899
38. Stunkard AJ, Messick S (1985) The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res 29:71-83
39. World Health Organization (1995) Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series, 854. World Health Organization, Geneva
40. Sepple CP, Read NW (1989) Gastrointestinal correlates of the development of hunger in man. Appetite 13:183-191
41. Green SM, Delargy HJ, Joanes D, Blundell JE (1997) A satiety quotient: a formulation to assess the satiating effect of food. Appetite 29:291-304
42. Santangelo A, Peracchi M, Conte D, Fraquelli M, Porrini M (1998) Physical state of meal affects gastric emptying, cholecystokinin release and satiety. Br J Nutr 80:521-527
43. MacIntosh CG, Morley JE, Wishart J et al (2001) Effect of exogenous cholecystokinin (CCK)-8 on food intake and plasma CCK, leptin, and insulin concentrations in older and young adults: evidence for increased CCK activity as a cause of the anorexia of aging. J Clin Endocrinol Metab 86:5830-5837
44. Linco Research. Available at: http://www.lincoresearch.com, last accessed in October 2004
45. Centers for Disease Control and Prevention (2004) Trends in intake of energy and macronutrients - United States, 1971-2000. MMWR Morb Mortal Wkly Rep 53:80-82
46. Lutz TA, Geary N, Szabady MM, Del Prete E, Scharrer E (1995) Amylin decreases meal size in rats. Physiol Behav 58:1197-1202
47. Rocca AS, Brubaker PL (1999) Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140:1687-1694
48. Lutz TA, Del Prete E, Scharrer E (1995) Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin. Peptides 16:457-462
49. Levetan C, Want L, Weyer C et al (2003) Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagons and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 26:1-8